Generic Kuvan is indicated to reduce blood phenylalanine levels in adult and pediatric patients one month of age or older with hyperphenylalaninemia due to tetrahydrobiopterin- (BH4-) responsive Phenylketonuria.
Chlorthalidone tablets are indicated for the management of hypertension either as the sole therapeutic agent or to enhance the effect of other antihypertensive drugs in the more severe forms of hypertension.
Novartis AG agreed to pay $245 million to end antitrust litigation accusing the company of trying to delay the launch of generic versions of the drug Exforge in the United States.
The Consolidated Appropriations Act will increase competition from generic and biosimilar medicines and enhance patient access to lower cost prescription drugs.